Commercial pharmaceutical partner, Inovail, successfully launches
OmegaGen(R) in Australia and New Zealand
LAVAL, QC, March 25 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) and its commercial pharmaceutical
partner Inovail Pty Ltd ("Inovail"), announce the successful launch of
OmegaGen(R) as a complementary medicine in Australia and New Zealand. Neptune
foresees this market entry as a commercial portal for Neptune into large
medicinal Asian Pacific markets.
Inovail in collaboration with PharmaLink, which ranks amongst the top
five sales organizations in the Australian pharmaceutical industry, is
promoting and marketing OmegaGen(R). OmegaGen(R), containing Neptune Krill Oil
(NKO(R)), is being initially distributed through retail pharmacies, health
food stores and healthcare professionals. As a short-term marketing objective,
Inovail seeks to distribute OmegaGen(R) in three thousand pharmacies.
"Our strong clinical evidence and established credibility in the industry
will help Inovail's brands achieve high levels of medical endorsement as
natural, evidence-based options for the improvement of cognitive function, and
chronic cholesterol and inflammation management," said Dr. Tina Sampalis,
Chief Scientific Officer of Neptune. "Additional product launches to expand
the complementary medicine franchise are planned in the following few months.
This strategy should allow Neptune to take full advantage of these products in
a combined potential market worth over 300 million$."
"We are very excited to be the first to launch Neptune Krill Oil, an
exceptional and innovative product. We expect to gain rapid and deep
penetration of the pharmacy and other healthcare channels," said Dr. Peter
Mayrick from Inovail. "Our market research has indicated that, when health
professionals and consumers of omega-3 fatty acids are presented the clinical
evidence for Neptune Krill Oil, they are suitably impressed."
Neptune Krill Oil is provided to Inovail through Neptune's regional
distributor, Azpa International, a leading supplier to the pharmaceutical and
nutritional health industries.
About Invida Pharmaceutical Holdings Pte. Ltd.
Invida Pharmaceutical Holdings Pte. Ltd. is the holding company of
Pharmalink, the leading pharmaceutical and healthcare commercialization
provider in Asia Pacific; and Inovail, an independently-managed specialty
pharmaceutical company focused on market-driven innovation in the areas of
dermatology, complementary oncology and female healthcare. Headquartered in
Singapore, Invida's focus is in the Asia Pacific region, where it has offices
in 13 countries. Invida's shareholders include Temasek Holdings, Quintiles
Transnational and the Zuellig Group. More information about Invida can be
found at www.invida.com.
About Neptune Technologies & Bioressources Inc.
Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical, medical food and pharmaceutical applications.
Through clinical research, Neptune is showing the clinical benefits of its
products in various therapeutic indications with a focus on cardiovascular and
cognitive health. The Company has been successful in patenting and protecting
its intellectual property, and will continue to protect its innovations.
Neptune has already obtained regulatory approvals allowing commercialization
of its products and has filed for and is expecting additional approvals.
Neptune continues to strongly support its strategic development plan to
form partnerships/strategic alliances with worldwide leaders in the
nutraceutical and pharmaceutical industries. Neptune has recently signed
agreements with Nestlé and Yoplait, worldwide leading food manufacturers,
paving its entrance into the global functional food market. According to its
business strategy, negotiations with pharmaceutical companies with the
objective of entering the pharmaceutical market by licensing rights are
Neither NASDAQ nor TSX venture exchange accepts responsibility for the
adequacy or accuracy of this press release.
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,